Uncategorized

Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail

Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail

Published

on

Sarepta Therapeutics is seeking to convert the accelerated approval of its therapeutic exon-skippers for Duchenne muscular dystrophy to full despite the drugs’ failure to improve motor function in a confirmatory trial.​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version